All In Biotech

NDA 020124 · US Army

Diazepam

Diazepam · Injection · Benzodiazepine

Discontinued

Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Dec 5, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

118

16 Phase 3, 6 recruiting

FAERS reports

90,056

76,641 serious, 20,859 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Diazepam injection, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...

What it is approved for

From the label in effect Dec 18, 2023.

INDICATIONS Diazepam is indicated for the management of anxiety disorders for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Note: Because the autoinjector provides a minimum dose of 10 mg diazepam, it should not be used to treat individuals with mild and moderate degrees of anxiety and anxiety related disorders that would ordinarily be managed with intramuscular doses of less than 10 mg. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (See WARNINGS ). Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is useful premedication for relief of anxiety and tension in patients who are to undergo surgical procedures.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 5, 1990 Original approval · Type 3 - New Dosage Form
1 products under this application
  • DIAZEPAM · DIAZEPAM 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.

All 118 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents9,224
  • drug abuse6,198
  • drug ineffective5,045
  • nausea4,204
  • drug interaction3,886
  • completed suicide3,880
  • fatigue3,807
  • somnolence3,636
  • off label use3,550
  • anxiety3,387
  • death3,387
  • headache3,270

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,140
20051,344
20061,170
20071,233
20081,797
20091,793
20102,345
20112,776
20123,252
20133,740
20143,767
20154,658
20165,306
20175,529
20186,524
20197,145
20206,726
20215,695
20224,983
20234,864
20245,151
20255,144
20263,963

Recalls

1 FDA enforcement reports for this application.

  • Jun 6, 2012 · Class II · Terminated

    Impurities/Degradation Products: High Out of Specification levels for carbostyril, a known degradation product of diazepam.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diazepam* (Diazepam)

2024 spending

$18.9M

Beneficiaries

928,913

2,984,541 claims

Per beneficiary

$20

$0.94 per unit

View as table
YearSpending
2020$26,863,476
2021$25,150,473
2022$22,908,990
2023$22,543,778
2024$18,938,266

Part B: Diazepam (Diazepam) · HCPCS J3360

2024 spending

$20K

Beneficiaries

1,310

2,217 claims

Per beneficiary

$15

2024 ASP limit $5.82 per unit

View as table
YearSpending
2020$34,215
2021$29,475
2022$23,863
2023$20,945
2024$20,065

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,534 on PubMed

Sponsor: US Army

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.